The 13th World ADC London returns in 2023 as Europe’s longest standing and definitive antibody-drug conjugate event – and it’s back bigger and better than before!

With the recent approvals of ImmunoGen’s ELAHERE, Astrazeneca and Daiichi Sankyo’s DESTINY-Breast04, supporting Enhertu’s use in HER2-low breast cancer as a new therapeutically targetable category, the ADC space has continued to make major waves throughout 2022, a joy to see for oncology patients around the world.

With high hopes set on Byondis for the next approval, you simply can’t miss out on this highly anticipated event. Exploring all aspects of ADC development from discovery to late-stage manufacturing, this is your one-stop shop for antibody-drug conjugate content.

No ADC stone is left unturned as we unite all leading players in the field under one roof. Wherever your interest and expertise lies, we have it covered at the industry’s leading conference to help forward-thinking researchers from the pharmaceutical, biotech, and academic community advance the development of antibody-drug conjugates.

With more speakers, content, and networking opportunities than ever before, this is set to be the best version of the event yet and you cannot afford to miss it!


Industry Pricing: Conference + Seminar Day + Workshop Day (Full 4 Day Access Pass): GBP 4595.00,
Industry Pricing: Conference + Seminar day OR Workshop Day (3 Day Pass): GBP 3597.00,
Industry Pricing: Conference only (2 Day Pass): GBP 2599.00,
Academic Pricing: Conference + Seminar Day + Workshop Day (Full 4 Day Access Pass): GBP 3695.00,
Academic Pricing: Conference + Seminar day OR Workshop Day (3 Day Pass): GBP 2897.00,
Academic Pricing – Conference only (2 Day Pass): GBP 2099.00,
Solution Provider Pricing: Conference + Seminar Day + Workshop Day (Full 4 Day Access Pass): GBP 5195.00,
Solution Provider Pricing: Conference + Seminar day OR Workshop Day (3 Day Pass): GBP 4197.00,
Solution Provider Pricing: Conference only (2 Day Pass): GBP 3199.00

Speakers: Aarti Jashnani, Principal Scientist, Bristol Myers Squibb, Abderrahman Laadem, Vice President, Global Head, Early Clinical Development, Daiichi Sankyo, Adam Taylor, Scientist, Defence Science and Technology Laboratory, Ahmed Bassyouni, Independent Consultant, Bassyouni Consulting, Alain Beck, Senior Director, Pierre Fabre Group, Alyson Smith, Director of Cancer Target Discovery, Seagen, Ana Hidalgo, Sastre Director, Translational Sciences, AstraZeneca, Andrea Galbiati, Research Scientist, Philochem, Andreas Pahl, Chief Scientific Officer, Heidelberg Pharma, Anette Weyergang, Project Leader, Oslo University, Anton Rosenbaum, Director, AstraZeneca, Ben Shen, Senior Director, Genentech, Benjamin Fabre, Scientist, Sanofi, Bin Deng, Senior Scientist, Eisai, Brian Clark, Principal Consultant, GMP Operations Consulting, Carolina Haefliger, Head of Translational Medicine, Debiopharm, Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies, Christian Rohlff, Chief Executive Officer, Oxford Biotherapeutics, Claudia De Lorenzo, Associate Professor, University of Naples Federico, Dan Milano, Director, Process Development, ImmunoGen, Dangshe Ma, Senior Director, Regeneron Pharmaceuticals Inc, David Bramhill, President and Founder, Bramhill Biological Consulting, David Newman, Consultant, NCI at Frederick, Dawn Spiller, Senior Director, Group Manager Regulatory CMC, AstraZeneca, Dorota Roberts, Associate Director, Technical Products, Seagen, Edith Perez, Chief Medical Officer, Bolt Therapeutics, Eline Van Den Berg, Research Scientist, Byondis, Federico Sirtori, Director, Head of NBEDMPK, Merck and Co., Francesca Zammarchi, Head of Preclinical Pharmacology, ADC Therapeutics, Gerold Meinhardt, Hematologist, Clinical Development Executive, Daiichi Sankyo, Giorgio Salciarini, Marketing and Business Development Manager, BSP Pharmaceuticals, Gordon Rigg, Principal Consultant, Apex Biologics Consulting, Greg Thurber, Associate Chair, University of Michigan, Gregory Adams, Chief Scientific Officer, Elucida Oncology, Henner Ebeling, Senior Scientist, Janssen, Hong Ren, Lead of Biologics Downstream Digital Development Group, Merck and Co., Huang Robert, Chief Executive Officer, Coherent Biopharma, Jan-Oliver Schwabe, Senior Site Manager, External Manufacturing, Roche, Jarrod Longcor, Chief Operating Officer, Cellectar Biosciences, Jon Van Dyck, Principal Scientist, Seagen, Jonathan Beadle, Senior Scientist, AstraZeneca, Jonathan Fawcett, Senior Director, Clinical Development, Exelixis, Juergen Scheuenpflug, Global Head, Clinical Biomarkers, Companion Diagnostics, Merck and Co., Justin Mason-Home, Director, HPAPI Project Services Limited, Lei Zhu, Senior Director, Head of Chemical Process and Supply Development, Mersana Therapeutics, Madhura Deshpande, Research Scientist, Bristol Myers Squibb, Manel Kraiem, Senior Project Manager, Innate Pharma, Manoj Chiney, Director, Clinical Pharmacology, Gilead Sciences, Marisa Schmitt, Director, Bioanalytics, Heidelberg Pharma, Mark Frigerio, Vice President, Chemistry, Bicycle Therapeutics, Martha Neagu, Medical Director, AbbVie, Martina McDermott, Adjunct Assistant Professor, UCLA, Mary Hu,Chief Executive Officer, Shanghai Miracogen, Michael Method, Executive Medical Director, ImmunoGen, Mike Liao, Principal Scientist, Genentech, Mostafa Nakach, Global Head of Process Engineering, Sanofi, Nathan Alves, Director of Translational Research, Assistant Professor, Indiana University School of Medicine, Nathan Ihle, Senior Vice President, CMC and Quality, Bolt Biotherapeutics, Neki Patel, Senior Research Scientist, AstraZeneca, Olga Ab, Lead Clinical Scientist, ImmunoGen, Paul Bulger, Director, Analytical Research and Development, Merck and Co., Paul Song, Chief Scientific Officer, Research and Development, Genequantum Healthcare, Rakesh Dixit, Chief Executive Officer, Bioavigen, Remy Gebleux, Senior Scientist, NBE Therapeutics, Robert Herbst, Vice President, Technical Operations, ImmunoGen, Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics, Romain Bonnot, Vice President, Global Head, Oncology, Novartis, Samuele Cazzamalli, Head of Small Molecule Therapeutics, Philochem, Shawn Novick, Principal Consultant, International Alliance for Biological Standardization, Shuwen Sun, Principal Scientist, Merck and Co., Sonia Jain, Research Associate, Mayo Clinic, Steffan Woell, Prinicpal Scientist, Merck KGaA, Stuart Barnscher, Director, Preclinical Programs, ADC Research, Zymeworks, Susan Clardy, Associate Director, Analytical CMC, Mersana Therapeutics, Tae Han, Chief Operating Officer and President, ProfoundBio, Torbjörn Gräslund, Professor, Division of Protein Engineering, KTH Royal Institute of Technology, Torsten Hechler, Vice President, ADC Research, Heidelberg Pharma, Trevor Hallam, Chief Scientific Officer and President Sutro, Biopharma, Vijay Chudasama, Professor, Organic Chemistry and Chemical Biology, University College London, Vincent Blot,Senior Scientific Director, AbbVie, Vivian Trang, Principal Scientist, Seagen, William Grossman, Senior Vice President, Oncology Clinical Development, Gilead Sciences, Ying Pan, Senior Director, Translational Science and Biomarkers, CStone Pharmaceuticals, Yogita Krishnamachari, Director, Merck and Co., Yutaka Matsuda, ADC Project Manager, Aji Bio-Pharma Services, Zhibo Liu, Assistant Professor and Principal Investigator, Peking University

Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Development

Date and Time: 13th March 2023 at 8:00 am to 16th March 2023 at 4:00 pm

Venue details: ExCeL London, 1 Western Gateway, London, England, E16 1XL, United Kingdom